<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-4085</journal-id>
<journal-title><![CDATA[Revista mexicana de urología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. urol.]]></abbrev-journal-title>
<issn>2007-4085</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-40852024000100003</article-id>
<article-id pub-id-type="doi">10.48193/xyr93b25</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Sensibilidad y especificidad del índice de salud prostática (PHI), para el escrutinio de cáncer prostático, evitando la práctica de biopsias innecesarias]]></article-title>
<article-title xml:lang="en"><![CDATA[Sensitivity and specificity of prostate health index (PHI), for the scrutiny of prostate cancer, avoiding the practice of unnecessary biopsies]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ángeles-Gómez]]></surname>
<given-names><![CDATA[Brenda Maleni]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castrejón-Delgado]]></surname>
<given-names><![CDATA[Lizett]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional Autónoma de México  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2024</year>
</pub-date>
<volume>84</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-40852024000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-40852024000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-40852024000100003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Determinar la sensibilidad y especificidad del índice de salud prostática (PHI) para el escrutinio de cáncer de próstata en población mexicana con niveles de antígeno prostático (PSA) total mayor a 4ng/mL, en un hospital de segundo nivel.  Método: Se realizó un estudio exploratorio, transversal analítico y retrospectivo, de tipo prueba diagnóstica, en un hospital de segundo nivel. Se recolectaron datos de 84 pacientes que fueron sometidos a biopsia de próstata, seleccionados mediante la revisión de estudios de laboratorio. Se midió la sensibilidad, especificidad, valores predictivo positivo y negativo, curva ROC y el área bajo la curva (AUC).  Resultados: La sensibilidad y especificidad del PHI obtenidas fue de 82 % y 84 % respectivamente. Consideramos como punto de corte óptimo 43 puntos dado por la curva ROC, con un área bajo la curva de 0.930; así mismo, el valor predictivo positivo fue de 72 % y el valor predictivo negativo de 90 %.  Limitaciones:  La limitación principal es el tamaño de muestra.  Originalidad:  Es necesario la aplicación de nuevos biomarcadores como método de cribado con una mayor confiabilidad para el diagnóstico de cáncer de próstata para evitar la práctica innecesaria de biopsias en población mexicana.  Conclusiones: El estudio demostró una sensibilidad y especificidad del índice de salud prostática (PHI) buena.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective:  To determine the sensitivity and specificity of the prostate health index (PHI) for prostate cancer screening in Mexican population with total prostate antigen (PSA) levels greater than 4ng/mL, in a second level hospital.  Method:  An exploratory, cross-sectional, retrospective, diagnostic test-type study was performed in a second level hospital. Data were collected from 84 patients who underwent prostate biopsy, selected through the review of laboratory studies. The sensitivity, specificity, positive and negative predictive values, ROC curve and the area under the curve (AUC) were measured.  Results:  The sensitivity and specificity of the PHI obtained was 82 % and 84 % respectively. We considered 43 points as the optimal cutoff given by the ROC curve, with an area under the curve of 0.930; likewise, the positive predictive value was 72 % and the negative predictive value was 90%.  Limitations:  The main limitation is the sample size.  Originality:  It is necessary the application of new biomarkers as a screening method with a greater reliability for the diagnosis of prostate cancer to avoid the unnecessary practice of biopsies in Mexican population.  Conclusions:  The study demonstrated a good prostate health index (PHI) sensitivity and specificity.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Diagnosis]]></kwd>
<kwd lng="en"><![CDATA[prostate cancer]]></kwd>
<kwd lng="en"><![CDATA[prostate specific antigen]]></kwd>
<kwd lng="en"><![CDATA[prostate health index]]></kwd>
<kwd lng="es"><![CDATA[Diagnóstico]]></kwd>
<kwd lng="es"><![CDATA[cáncer de próstata]]></kwd>
<kwd lng="es"><![CDATA[antígeno prostático específico]]></kwd>
<kwd lng="es"><![CDATA[índice de salud prostática]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leslie]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Soon-Sutton]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[R I]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sajjad]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Skelton]]></surname>
<given-names><![CDATA[WP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate Cancer]]></article-title>
<source><![CDATA[StatPearls]]></source>
<year>2024</year>
<publisher-loc><![CDATA[Treasure Island (FL) ]]></publisher-loc>
<publisher-name><![CDATA[StatPearls Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Islas Pérez]]></surname>
<given-names><![CDATA[LÁ]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Reséndiz]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz Hernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ruvalcaba Ledezma]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Benítez Medina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Beltran Rodríguez]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiología del cáncer de próstata, sus determinantes y prevención]]></article-title>
<source><![CDATA[Journal of Negative and No Positive Results]]></source>
<year>2020</year>
<volume>5</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1010-22</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castillejos-Molina]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Gabilondo-Navarro]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[Castillejos-Molina]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Gabilondo-Navarro]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate cancer]]></article-title>
<source><![CDATA[Salud Pública de México]]></source>
<year>2016</year>
<volume>58</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>279-84</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jara Rascón]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Subirá Ríos]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[LLedó García]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Salamanca]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Moncada Iribarren]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Fernández]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación del antígeno especifico prostático (PSA) ajustado al volumen de la zona transicional en la detección del cáncer de próstata]]></article-title>
<source><![CDATA[Actas Urológicas Españolas]]></source>
<year>2005</year>
<volume>29</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>485-92</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morejón]]></surname>
<given-names><![CDATA[WV]]></given-names>
</name>
<name>
<surname><![CDATA[Sena]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Vega]]></surname>
<given-names><![CDATA[YP]]></given-names>
</name>
<name>
<surname><![CDATA[Águila Y de la]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[IC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antígeno prostático específico como predictor del diagnóstico de adenocarcinoma prostático]]></article-title>
<source><![CDATA[Revista Finlay]]></source>
<year>2015</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>221-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gelpi-Méndez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Fernández]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Martín-Barallat]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cortés-Arcas]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Monsonis-Artero]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Calvo-Mora]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valores de referencia del antígeno prostático específico (PSA) en 63.926 trabajadores sin síntomas prostáticos que participaron en el cribado de cáncer de próstata desarrollado por la Sociedad de Prevención de Ibermutuamur durante el año 2006]]></article-title>
<source><![CDATA[Actas Urológicas Españolas]]></source>
<year>2010</year>
<volume>34</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>669-76</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[De Cobelli]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Lucarelli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Porreca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Busetto]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Cantiello]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beyond PSA: The Role of Prostate Health Index (phi)]]></article-title>
<source><![CDATA[International Journal of Molecular Sciences]]></source>
<year>2020</year>
<volume>21</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1184</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zegarra-Montes]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sarria-Bardales]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Perez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Del-Castillo-Pacora]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dyer-Velarde-Álvarez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Trelles-De-Belaunde]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Viabilidad y seguridad de la biopsia prostática transperineal en la era de fusión de imágenes por resonancia magnética cognitiva/ultrasonido en la detección del cáncer]]></article-title>
<source><![CDATA[Acta Médica Peruana]]></source>
<year>2022</year>
<volume>39</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nordström]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Vickers]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Assel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lilja]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Grönberg]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Eklund]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer]]></article-title>
<source><![CDATA[European Urology]]></source>
<year>2015</year>
<volume>68</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>139-46</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lepor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Catalona]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Loeb]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Prostate Health Index]]></article-title>
<source><![CDATA[Urologic Clinics of North America]]></source>
<year>2016</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yáñez-Castillo]]></surname>
<given-names><![CDATA[YM]]></given-names>
</name>
<name>
<surname><![CDATA[Melgarejo-Segura]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Funes-Padilla]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Folgueral-Corral]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[García-Larios]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Arrabal-Polo]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate health index (PHI) as an accurate prostate cancer predictor]]></article-title>
<source><![CDATA[Journal of Cancer Research and Clinical Oncology]]></source>
<year>2023</year>
<volume>149</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>9329-35</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seisen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Rouprêt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brault]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Léon]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cancel-Tassin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Compérat]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy: PHI vs. PCA-3 to Detect Overall and Significant Prostate Cancer]]></article-title>
<source><![CDATA[The Prostate]]></source>
<year>2015</year>
<volume>75</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>103-11</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PSA and beyond: alternative prostate cancer biomarkers]]></article-title>
<source><![CDATA[Cellular Oncology]]></source>
<year>2016</year>
<volume>39</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>97-106</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farha]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Salami]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomarkers for prostate cancer detection and risk stratification]]></article-title>
<source><![CDATA[Therapeutic Advances in Urology]]></source>
<year>2022</year>
<volume>14</volume>
<page-range>175628722211039</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abrate]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lughezzani]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gadda]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Lista]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kinzikeeva]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fossati]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature]]></article-title>
<source><![CDATA[Korean Journal of Urology]]></source>
<year>2014</year>
<volume>55</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>436</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De La Calle]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Patil]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Scherr]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Sokoll]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men]]></article-title>
<source><![CDATA[Journal of Urology]]></source>
<year>2015</year>
<volume>194</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>65-72</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chiu]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[YT]]></given-names>
</name>
<name>
<surname><![CDATA[Pu]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate Health Index Density Outperforms Prostate Health Index in Clinically Significant Prostate Cancer Detection]]></article-title>
<source><![CDATA[Frontiers in Oncology]]></source>
<year>2021</year>
<volume>11</volume>
<page-range>772182</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Le]]></surname>
<given-names><![CDATA[BV]]></given-names>
</name>
<name>
<surname><![CDATA[Griffin]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Loeb]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalhal]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
<name>
<surname><![CDATA[Kan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Baumann]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[[-2]Proenzyme Prostate Specific Antigen is More Accurate Than Total and Free Prostate Specific Antigen in Differentiating Prostate Cancer From Benign Disease in a Prospective Prostate Cancer Screening Study]]></article-title>
<source><![CDATA[Journal of Urology]]></source>
<year>2010</year>
<volume>183</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1355-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stephan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vincendeau]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Houlgatte]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cammann]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Semjonow]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multicenter Evaluation of [&#8722;2]Proprostate-Specific Antigen and the Prostate Health Index for Detecting Prostate Cancer]]></article-title>
<source><![CDATA[Clinical Chemistry]]></source>
<year>2013</year>
<volume>59</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>306-14</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loeb]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sokoll]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Broyles]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Bangma]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Van Schaik]]></surname>
<given-names><![CDATA[RHN]]></given-names>
</name>
<name>
<surname><![CDATA[Klee]]></surname>
<given-names><![CDATA[GG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration]]></article-title>
<source><![CDATA[Journal of Urology]]></source>
<year>2013</year>
<volume>189</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1702-6</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study]]></article-title>
<source><![CDATA[Journal of Korean Medical Science]]></source>
<year>2018</year>
<volume>33</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lazzeri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Haese]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Abrate]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[De La Taille]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Redorta]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[McNicholas]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical performance of serum prostate&#8208;specific antigen isoform [&#8208;2] PROPSA ( P2PSA ) and its derivatives, % P2PSA and the prostate health index ( PHI ), in men with a family history of prostate cancer: results from a multicentre E uropean study, the PROMETHEUS project]]></article-title>
<source><![CDATA[BJU International]]></source>
<year>2013</year>
<volume>112</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>313-21</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Filella]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Giménez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of [&#8722;2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Clinical Chemistry and Laboratory Medicine]]></source>
<year>2013</year>
<volume>51</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>729-39</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Agnello]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vidali]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Giglio]]></surname>
<given-names><![CDATA[RV]]></given-names>
</name>
<name>
<surname><![CDATA[Gambino]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Ciaccio]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Lo Sasso]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Clinical Chemistry and Laboratory Medicine]]></source>
<year>2022</year>
<volume>60</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1261-77</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopes Vendrami]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chatterjee]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Casalino]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Schaeffer]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Catalona]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Utility of Prostate Specific Antigen Density, Prostate Health Index, and Prostate Health Index Density in Predicting Positive Prostate Biopsy Outcome is Dependent on the Prostate Biopsy Methods]]></article-title>
<source><![CDATA[Urology]]></source>
<year>2019</year>
<volume>129</volume>
<page-range>153-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
